Sources: 1BitterDB, 4ClinicalTrials, 10DGIdb, 14DrugBank, 16FDA, 29HMDB, 33IUPHAR, 44NCI, 46NDF-RT, 50Novoseek, 56PharmGKB, 68UMLSSee all MalaCards sources |
FDA approved drugs:
| id |
|
Drug Name |
Active Ingredient(s)16 |
Company |
Approval Date |
| 1 |
|
Ibrance16 44 |
PALBOCICLIB |
Pfizer |
February 2015 |
Disease/s that Drug Treats:ER-positive, HER2-negative breast cancer
Indications and Usage:16 IBRANCE is a kinase inhibitor indicated in combination with letrozole for thetreatment of postmenopausal women with estrogen receptor (ER)-positive,human epidermal growth factor receptor 2 (HER2)-negative advanced breastcancer as initial endocrine-based therapy for their metastatic disease. Thisindication is approved under accelerated approval based on progression-freesurvival (PFS). Continued approval for this indication may be contingentupon verification and description of clinical benefit in a confirmatory trial. (1)
DrugBank Targets:14 1. Cyclin-dependent kinase 4;2. Cyclin-dependent kinase 6
Mechanism of Action:16
Target: cyclin-dependent kinase (CDK) 4 and 6
Action: inhibitor
FDA: Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. Cyclin D1 and CDK4/6 aredownstream of signaling pathways which lead to cellular proliferation. In vitro, palbociclib reducedcellular proliferation of estrogen receptor (ER)-positive breast cancer cell lines by blocking progressionof the cell from G1 into S phase of the cell cycle. Treatment of breast cancer cell lines with thecombination of palbociclib and antiestrogens leads to decreased retinoblastoma protein (Rb)phosphorylation resulting in reduced E2F expression and signaling and increased growth arrestcompared to treatment with each drug alone. In vitro treatment of ER-positive breast cancer cell lineswith the combination of palbociclib and antiestrogens leads to increased cell senescence, which wassustained for up to 6 days following drug removal. In vivo studies using a patient-derived ER-positivebreast cancer xenograft model demonstrated that the combination of palbociclib and letrozole increasedthe inhibition of Rb phosphorylation, downstream signaling and tumor growth compared to each drugalone.
|
| 2 |
|
Tasigna16 44 |
NILOTINIB HYDROCHLORIDE MONOHYDRATE |
Novartis |
October 2007 |
Disease/s that Drug Treats:chronic myelogenous leukemia
Indications and Usage:16 Tasigna is a kinase inhibitor indicated for:The treatment of newly diagnosed adult patients with Philadelphiachromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.The treatment of chronic phase (CP) and accelerated phase (AP) Ph+ CML inadult patients resistant to or intolerant to prior therapy that included imatinib.(1.2)--------------
DrugBank Targets:14 1. Tyrosine-protein kinase ABL1;2. Mast/stem cell growth factor receptor Kit
Mechanism of Action:16
Target: Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF)
Action: inhibitor of signal transduction
FDA: Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation ofthe kinase domain of ABL protein. In vitro, nilotinib inhibited BCR-ABL mediated proliferation of murineleukemic cell lines and human cell lines derived from patients with Ph+ CML. Under the conditions of theassays, nilotinib was able to overcome imatinib resistance resulting from BCR-ABL kinase mutations, in 32 outof 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine BCR-ABL xenograft model.Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: BCR-ABL (20to 60 nM), PDGFR (69 nM), c-KIT (210 nM), CSF-1R (125 to 250 nM), and DDR1 (3.7 nM).
|
| 3 |
|
Kalydeco16 |
IVACAFTOR |
Vertex Pharmaceuticals |
January of 2012 |
Disease/s that Drug Treats:cystic fibrosis with the G551D mutation in the CFTR gene
Indications and Usage:16 KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. KALYDECO is indicated for the treatment of CF in patients age 6 years and older who have an R117H mutation in the CFTR gene. If the patientâs genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. (1) Limitations of Use: * Not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene. (1, 14)
DrugBank Targets:14 Cystic fibrosis transmembrane conductance regulator
Mechanism of Action:16
Target: cystic fibrosis transmembrane conductance regulator (CFTR)
Action: potentiator
FDA: Ivacaftor is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein. In vitro, ivacaftor increased CFTR-mediated transepithelial current (IT) in rodent cells expressing the G551D-CFTR protein following addition of a cyclic adenosine monophosphate (cAMP) agonist with an EC50 of 100 ± 47 nM; however, ivacaftor did not increase IT in the absence of cAMP agonist. Ivacaftor also increased IT in human bronchial epithelial cells expressing G551D-CFTR protein following addition of a cAMP agonist by 10-fold with an EC50 of 236 ± 200 nM. Ivacaftor increased the open probability of G551D-CFTR protein in single channel patch clamp experiments using membrane patches from rodent cells expressing G551D-CFTR protein by 6-fold versus untreated cells after addition of PKA and ATP. In addition to G551D-CFTR, ivacaftor increased the channel-open probability of other mutant CFTR forms expressed in rodent cells, resulting in enhanced CFTR-mediated IT. These mutant CFTR forms included G178R-, S549N-, S549R-, G551S-, G970R-, G1244E-, S1251N-, S1255P-, and G1349D-CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has low channel-open probability (gating) and reduced channel current amplitude (conductance) compared to normal CFTR. In vitro responses do not necessarily correspond to in vivo pharmacodynamic response or clinical benefit.
|
Drugs for Retinoblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show top 50)
(show all 149)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Etoposide | approved | Phase 4, Phase 3, Phase 2, Phase 1 | 1269 | 33419-42-0 | 36462 | (-)-Etoposide 121471-01-0 136598-18-0 201594-04-9 33419-42-0 35317-32-9 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside 4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside 51854-34-3 76576-58-4 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one AB00438905 AC1L1FN8 AC1L1VT3 AC1L6246 AC1NR4OG AC1O4WGG AC1O7M1N AC1Q47JJ Ambap33419-42-0 BPBio1_000673 BRD-K37798499-001-02-5 BSPBio_000611 Bio1_000489 Bio1_000978 Bio1_001467 C01576 CCRIS 2392 CHEBI:4911 CHEBI:588795 CHEMBL44657 CID11758093 CID284997 CID3310 CID36462 CID5284558 CID6419930 CID6610299 CPD000112002 D00125 DB00773 DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE, Demethyl Epipodophyllotoxin Ethylidine Glucoside Demethyl-epiodophyllotoxin ethylidene glucoside Demethylepipodophyllotoxin-beta-D-ethylideneglucoside E0675 E1383_SIGMA EINECS 251-509-1 EPE EPEG ETOP Epipodophyllotoxin Epipodophyllotoxin VP-16213 Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside) Eposide Eposin | Eposin, Vepesid, VP-16, Toposar, Etoposide Etopol Etopophos Etopophos (phosphate salt) Etoposid Etoposide Etoposide (JP15/USP/INN) Etoposide (VP16) Etoposide [USAN:INN:BAN:JAN] Etoposido Etoposido [INN-Spanish] Etoposidum Etoposidum [INN-Latin] Etosid HMS1569O13 HMS2052N05 HMS2089F14 HSDB 6517 I06-0248 KBioSS_002410 LS-1214 Lastet MLS000049957 MLS001074951 MLS001424283 MLS002153463 MLS002207239 MLS002222184 MolPort-003-983-431 MolPort-004-905-001 MolPort-004-955-161 NCGC00025056-02 NChemBio.2007.10-comp19 NK 171 NSC 141540 NSC-141540 NSC141540 Prestwick0_000396 Prestwick1_000396 Prestwick2_000396 Prestwick3_000396 Prestwick_211 S1225_Selleck SAM001246880 SMR000112002 SPBio_002532 ST056353 Toposar UNII-6PLQ3CP4P3 VP 16 VP 16 (pharmaceutical) VP 16-213 VP 16213 VP-16 VP-16-213 VePESID (TN) VePesid Vepesid Vepesid J Vepeside ZINC03830818 ZINC03938684 Zuyeyidal etoposide nchembio.573-comp8 nchembio873-comp2 trans-Etoposide |
| | 2 | | Vincristine | approved, investigational | Phase 4, Phase 3, Phase 2 | 922 | 2068-78-2, 57-22-7 | 5978 | 22-Oxovincaleukoblastin 22-Oxovincaleukoblastine 28379-27-3 57-22-7 AC1L1LJC C07204 C46H56N4O10 CCRIS 5763 CHEBI:28445 CID5978 D08679 DB00541 EINECS 200-318-1 HMS2090E19 HSDB 3199 Indole alkaloid LCR LS-228 Leurocristine Lilly 37231 (1:1 sulfate salt) Liposomal Vincristine Marqibo NCGC00163700-01 NCI-C04864 NCI60_026703 NSC-67574 Onco TCS | Oncovin Oncovin (1:1 sulfate salt) Oncovine Tecnocris Tecnocris (TN) UNII-5J49Q6B70F VCR VIN Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine Vincasar Vincasar (1:1 sulfate salt) Vincasar PFS Vincrex Vincrex (1:1 sulfate salt) Vincristin Vincristina Vincristina [DCIT] Vincristine (INN) Vincristine Sulfate Vincristine Sulfate PFS Vincristine [INN:BAN] Vincristinum Vincristinum [INN-Latin] Vincrstine Vincrystine Vinkristin Z-D-Val-Lys(Z)-OH vincristine | |
| | 3 | | Carboplatin | approved | Phase 4, Phase 3, Phase 2, Phase 1 | 2050 | 41575-94-4 | 10339178, 498142, 38904 | (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum /h1-3H2,(H,7,8)(H,9,10) /q 1,1-Cyclobutanedicarboxylate diammine platinum (II) 1,1-Cyclobutanedicarboxylate diammine platinum(II) 2*-1 2*1H2 41575-94-4 70903-55-8 AC-1457 AC1L8I6U Ambap41575-94-4 BSPBio_003145 C 2538 C2043 C2538_SIGMA C6H10N2O4Pt CBDCA CCRIS 3404 CHEBI:31355 CHEMBL1351 CHEMBL288376 CID10339178 CID2567 CID38904 CID426756 CID498142 CID5352133 CID6398587 CID6603770 Carbopaltin Carboplatin Carboplatin (JAN/USP/INN) Carboplatin (USAN) Carboplatin [USAN:INN:BAN:JAN] Carboplatine Carboplatine [French] Carboplatino Carboplatino [Spanish] Carboplatinum Carboplatinum [Latin] Cbdca Cyclobutane-1,1-dicarboxylate D01363 DB00958 Diammine(1,1-cyclobutanedicarboxylato)platinum (II) Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum Diammine-1,1-cyclobutane dicarboxylate platinum II DivK1c_000892 EINECS 255-446-0 EU-0100230 Ercar HMS1921J16 HMS2090M05 HMS2092B22 HMS502M14 HSDB 6957 I14-2390 IDI1_000892 IUPAC: Azane InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6 | JM 8 JM-8 KBio1_000892 KBio2_002009 KBio2_004577 KBio2_007145 KBio3_002645 KBioGR_000713 KBioSS_002009 LS-117689 Lopac-C-2538 Lopac0_000230 MolPort-003-665-501 MolPort-003-845-609 NCGC00015223-01 NCGC00093695-01 NCGC00094961-01 NCGC00094961-02 NCGC00094961-03 NCGC00162099-01 NCGC00162099-02 NCGC00167800-01 NCGC00178242-01 NINDS_000892 NSC 201345 NSC 241240 NSC-241240 NSC201345 NSC241240 Paraplatin Paraplatin (TN) Paraplatin, Carboplatin Paraplatin-AQ Platinum(+2) Cation Platinum(II), (1, 1-cyclobutanedicar Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2) Platinum, {diammine[1,1-cyclobut S1215_Selleck SPBio_000716 SPECTRUM1502106 Spectrum2_000898 Spectrum3_001503 Spectrum4_000337 Spectrum5_001094 Spectrum_001529 UNII-BG3F62OND5 azanide carboplatin cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii) cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II) cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II) cis-Diammine(1,1-cyclobutanedicarboxylato) platinum cis-Diammine(1,1-cyclobutanedicarboxylato)platinum cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) cis-Diammine(cyclobutanedicarboxylato)platinum II cyclobutane-1,1-dicarboxylic acid diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum nchembio.573-comp10 nchembio773-comp2 nchembio873-comp3 platinum(2+) |
| | 4 | | Itraconazole | approved, investigational | Phase 4 | 158 | 84625-61-6 | 55283 | (+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one (+/-)-1-[( R *)- sec -butyl]-4-[ p -[4-[ p -[[(2 R *,4 S *)-2-(2,4-dichlorophenyl)-2-(1 H -1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-(DELTA) 2 1,2,4-triazolin-5-one mixture with (+/-)-1-[( R *)- sec -butyl]-4-[ p -[4- [ p -[[(2 S *,4 R *)-2-(2,4-dichlorophenyl)-2-(1 H -1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl] phenyl]-(DELTA) 2 -1,2,4-triazolin-5-one (1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one 2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one 2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl) 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 84604-65-9 84625-61-6 AC-542 AC1L1GQ5 AC1L1IRU AC1OCEL7 AC1Q6EZ3 AKOS000280875 Ambap84625-61-6 BIDD:GT0796 BRN 6042047 C35H38Cl2N8O4 CHEBI:6076 CHEMBL22587 CHEMBL882 CID3793 CID55283 CID6917738 CID9961741 CPD000058959 Canadiol D00350 DB01167 EINECS 283-347-2 FT-0082511 HMS2051K14 HMS2090M20 Hyphanox I01-1043 I0732 ITC ITCZ ITZ Intraconazole | Itraconazol Itraconazol [Spanish] Itraconazole Itraconazole & Bovine Lactoferrin Itraconazole & Nyotran Itraconazole & Nyotran(Liposomal Nystatin) Itraconazole (JAN/USAN) Itraconazole [USAN:BAN:INN:JAN] Itraconazole oral solution Itraconazolum Itraconazolum [Latin] Itrizole Itrizole (TN) Itrizole (tn) LS-1843 MLS000028582 MLS000759472 MLS000863291 MLS001148245 MolPort-000-883-864 MolPort-003-848-295 NCGC00089812-03 Oriconazole Oriconazole, R51211, Sporanox Orungal Prokanazol R 51211 R-51211 S2476_Selleck SAM001246679 SMR000058959 Sempera Spherazole Sporal Sporanos Sporanox Sporanox (TN) Sporanox (tn) Sporonox TL8005525 Triasporn UNII-304NUG5GF4 cis-Itraconazole itraconazole | |
| | 5 | | Lenograstim | approved | Phase 4, Phase 3, Phase 2, Phase 1 | 1220 | 135968-09-1 | | G-CSF (CHO cell derived) Glycosylated recombinant G-CSF Glycosylated recombinant granulocyte colony stimulating factor | Granulocyte colony stimulating factor 3 (CHO cell derived) Granulocyte colony-stimulating factor lenograstim Lenograstim (genetical recombination) Lenograstim rDNA | |
| | 6 | | Miconazole | approved, investigational, vet_approved | Phase 4, Phase 2, Phase 1 | 3706 | 22916-47-8 | 4189 | (+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole 1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole 1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole 1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole 1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole 22832-87-7 (NITRATE) 22916-47-8 75319-47-0 AB00053500 AC1L1HM1 AKOS001574474 Aflorix(nitrate) Albistat(nitrate) Andergin(nitrate) BPBio1_000279 BRD-A82396632-001-03-0 BRD-A82396632-008-02-7 BRN 0965511 BSPBio_000253 BSPBio_002033 CCRIS 7924 CHEBI:6923 CHEMBL91 CID4189 CPD-4501 Conofite(nitrate) D00416 DB01110 Dactarin Daktarin IV Daktarin iv DivK1c_000156 EINECS 245-324-5 Epi-Monistat(nitrate) Femizol-M Florid(nitrate) Gyno-Daktar(nitrate) HMS1568M15 HMS2090B21 I14-14342 IDI1_000156 Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI) KBio1_000156 KBio2_001445 KBio2_004013 KBio2_006581 KBio3_001533 KBioGR_000581 KBioSS_001445 LS-78378 Lotrimin AF(nitrate) MCZ MJR 1762 MLS002222203 Micantin (nitrate) Miconasil Nitrate | Miconazol Miconazol [INN-Spanish] Miconazole Miconazole (JP15/USP/INN) Miconazole 3 Miconazole 3 Combination Pack Miconazole 7 Combination Pack Miconazole [USAN:BAN:INN:JAN] Miconazole nitrate salt Miconazole-7 Miconazolo Miconazolo [DCIT] Miconazolum Miconazolum [INN-Latin] Micozole Minostate MolPort-002-557-553 Monazole 7 Monista (nitrate) Monistat Monistat (TN) Monistat 1 Combination Pack Monistat 3 Dual-Pak Monistat 3 Vaginal Ovules Monistat 5 Tampon Monistat 7 Dual-Pak Monistat 7 Vaginal Suppositories Monistat Dual- PAK Monistat IV Monistat iv (TN) Monistat iv (tn) Monistat-Derm NCI60_001353 NCI60_001380 NINDS_000156 NSC 170986 NSC169434 NSC170986 Novo-Miconazole Vaginal Ovules Oprea1_091955 Prestwick0_000067 Prestwick1_000067 Prestwick2_000067 Prestwick3_000067 Prestwick_335 R 18134 R-14,889 SMR001307249 SPBio_000976 SPBio_002174 STK834405 STOCK1S-93556 Spectrum2_001048 Spectrum3_000507 Spectrum4_000061 Spectrum5_001297 Spectrum_000965 UNII-7NNO0D7S5M Vusion Zimycan imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI) miconazole | |
| | 7 | | Nicotine | approved | Phase 4 | 1103 | 54-11-5 | 942, 89594 | (− (+)-Nicotine (-)-3-(1-Methyl-2-pyrrolidyl)pyridine (-)-3-(N-Methylpyrrolidino)pyridine (-)-Nicotine (-)-Nicotine solution (2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine (R)-3-(1-Methyl-2-pyrrolidinyl)pyridine (R,S)-Nicotine (S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE (S)-(-)-Nicotine (S)-(−)-nicotine (S)-3-(1-methylpyrrolidin-2-yl)pyridine (S)-3-(N-methylpyrrolidin-2-yl)pyridine (S)-Nicotine (−)-nicotine )-1-Methyl-2-(3-pyridyl)pyrrolidine )-Nicotine )-Nicotine solution 1-Methyl-2-(3-pyridal)-Pyrrolidine 1-Methyl-2-(3-pyridal)-pyrrolidene 1-Methyl-2-(3-pyridiyl)pyrrolidine 1-Methyl-2-(3-pyridyl)pyrrolidine 1uw6 2'-beta-H-Nicotine 3-(1-Methyl-2-pyrollidinyl)pyridine 3-(1-Methyl-2-pyrrolidinyl)-Pyridine 3-(1-Methyl-2-pyrrolidinyl)pyridine 3-(1-Methylpyrrolidin-2-yl)pyridine 3-(2-(N-methylpyrrolidinyl))pyridine 3-(N-Methylpyrollidino)pyridine 3-(N-Methylpyrrolidino)pyridine 3-(N-methylpyrollidino)pyridine 3-N-Methylpyrrolidine 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine 36733_FLUKA 36733_RIEDEL 434F7990-3240-4A43-ACEC-E6CC1E495FA0 46343_FLUKA 46343_RIEDEL 54-11-5 AC1L3I79 AC1Q3ZOC AI3-03424 BB_NC-0777 BIDD:GT0599 BRD-K05395900-322-02-1 Black Leaf Black Leaf 40 C00745 CCRIS 1637 CHEBI:17688 CHEMBL3 CID89594 CPD000059074 Campbell's Nico-Soap Caswell No. 597 Commit D-Nicotine D03365 DL-tetrahydronicotyrine Destruxol Destruxol Orchid Spray EINECS 200-193-3 ENT 3,424 EPA Pesticide Chemical Code 056702 Emo-Nik Flux Maag Fumeto bac Fumetobac HSDB 1107 Habitrol Habitrol (TN) L(-)-nicotine L(−)-nicotine L-3-(1-Methyl-2-pyrrolidyl)pyridine | L-Nicotine LS-202 MLS001055457 MLS001335905 Mach-Nic Methyl-2-pyrrolidinyl)pyridine Micotine MolPort-000-744-731 N3876_SIGMA N5511_FLUKA N5511_SIGMA NCGC00090693-01 NCGC00090693-02 NCGC00090693-03 NCGC00090693-04 NCGC00090693-05 NCGC00090693-06 NCGC00090693-07 NCT NICOTINE AND SALTS NSC 5065 NSC97238 Niagara P.A. Dust Nic-Sal Nico-Dust Nico-Fume Nicocide Nicoderm Nicoderm Cq Nicoderm Patch Nicorette Nicorette Plus Nicotin Nicotina Nicotina [Italian] Nicotine Nicotine (USP) Nicotine (compounds related to) Nicotine Alkaloid Nicotine Patch Nicotine Polacrilex Nicotine [BSI:ISO] Nicotine [UN1654] Nicotine [UN1654] [Poison] Nicotine [USAN] Nicotrol Nicotrol Inhaler Nicotrol Ns Nictoine patch Nikotin Nikotin [German] Nikotyna Nikotyna [Polish] Ortho N-4 Dust Ortho N-5 Dust PDSP1_000113 PDSP1_000465 PDSP2_000463 PDSP2_000555 Prostep R)-(+)-Nicotine RCRA waste no. P075 RCRA waste number P075 SAM002564224 SDCCGMLS-0066911.P001 SMR000059074 Tendust Transdermal Nicotine UN1654 a -N-Methylpyrrolidine a-N-Methylpyrrolidine alpha-N-Methylpyrrolidine beta-Pyridyl-alpha-N-methyl pyrrolidine beta-Pyridyl-alpha-N-methylpyrrolidine bmse000105 delta-Nicotine nicotine nicotine replacement patch |
| | 8 | | Ginseng | approved, nutraceutical | Phase 4, Phase 2 | 96 | 50647-08-0 | | Aralia ginseng root Asian ginseng Asian ginseng root Chinese ginseng root Ginseng (panax ginseng) Ginseng extract Ginseng, asian Hong shen root Insam root Korean ginseng | Korean ginseng root Ninjin root Panax ginseng Panax ginseng root Panax ginseng root extract Panax schinseng root Panax verus root Red ginseng Ren seng root Ren shen Ren shen root True ginseng root |
| | 9 | | Topoisomerase Inhibitors | | Phase 4, Phase 3, Phase 2, Phase 1 | 5069 | | | | 10 | | Antimitotic Agents | | Phase 4, Phase 3, Phase 2, Phase 1 | 5657 | | | | 11 | | Antineoplastic Agents, Phytogenic | | Phase 4, Phase 3, Phase 2, Phase 1 | 5602 | | | | 12 | | Etoposide phosphate | | Phase 4, Phase 3, Phase 2, Phase 1 | 1269 | | | | 13 | | Anti-Infective Agents | | Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 1 | 22062 | | | | 14 | | Ibandronic acid | | Phase 4 | 80 | | | | 15 | | Adjuvants, Immunologic | | Phase 4, Phase 3, Phase 2, Phase 1 | 2554 | | | | 16 | | Bone Density Conservation Agents | | Phase 4, Phase 2 | 3376 | | | | 17 | | Curcumin | | Phase 4 | 146 | 458-37-7 | 969516 | 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione 1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione 1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione C.I. Natural Yellow 3 CI Natural Yellow 3 Cucurmin Curcuma Curcumin Curcumin I Diferaloylmethane Diferuloylmethane Gelbwurz Golden seal Haidr Halad Haldar Halud Hydrastis | Indian saffron Indian turmeric Kacha haldi Kurkumin [czech] Merita earth Natural yellow 3 Orange root Safran D'inde Souchet Terra merita Tumeric yellow Turmeric Turmeric (>98% curcurmin) Turmeric oleoresin (79%-85% curcumin) Turmeric yellow Yellow ginger Yellow puccoon Yellow root Yo-kin Zlut prirodni 3 [Czech] |
| | 18 | | Liver Extracts | | Phase 4, Phase 2, Phase 1 | 4067 | | | | 19 | | Diphosphonates | | Phase 4 | 450 | | | | 20 | | Steroid Synthesis Inhibitors | | Phase 4, Phase 2, Phase 1 | 1763 | | | | 21 | | Cytochrome P-450 Enzyme Inhibitors | | Phase 4 | 3917 | | | | 22 | | Cytochrome P-450 CYP3A Inhibitors | | Phase 4 | 1715 | | | | 23 | | Antifungal Agents | | Phase 4, Phase 2, Phase 1 | 3696 | | | | 24 | | Hormones | | Phase 4, Phase 2, Phase 1 | 14415 | | | | 25 | | Hormone Antagonists | | Phase 4, Phase 2, Phase 1 | 13180 | | | | 26 | | Hormones, Hormone Substitutes, and Hormone Antagonists | | Phase 4, Phase 2, Phase 1 | 13168 | | | | 27 | | Hydroxyitraconazole | | Phase 4 | 158 | | | | 28 | | Allantoin | Nutraceutical | Phase 4 | 10 | 97-59-6 | 204 | (S)-allantoin 2,5-Dioxo-4-imidazolidinyl-urea 4-Ureido-2,5-Imidazolidinedione 5-Ureido-Hydantoin 5-Ureidohydantoin 5-Ureidohydrantoin AVC/Dienestrolcream Alantan Allantoin Allantol | Alloxantin Cordianine D00121 Fancol TOIN Glyoxyldiureid Glyoxyldiureide Glyoxylic diureide N-(2,5-Dioxo-4-imidazolidinyl)urea Psoralon Sebical Septalan | |
| | 29 | | Cyclophosphamide | approved, investigational | Phase 3, Phase 2, Phase 1, Early Phase 1 | 2935 | 50-18-0, 6055-19-2 | 2907 | (+-)-Cyclophosphamide (-)-Cyclophosphamide (RS)-Cyclophosphamide 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide 4-Hydroxy-cyclophosphan-mamophosphatide 50-18-0 60007-95-6 6055-19-2 (monohydrate) 75526-90-8 AC1L1EQQ AI3-26198 ASTA ASTA B518 Anhydrous cyclophosphamide Asta B 518 B 518 B-518 BRN 0011744 BSPBio_002099 Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester C 0768 C07888 C7H15Cl2N2O2P CB 4564 CB-4564 CCRIS 188 CHEBI:4027 CHEMBL32520 CHEMBL88 CID2907 CP CPA CTX CY Ciclofosfamida Ciclofosfamida [INN-Spanish] Ciclofosfamide Ciclophosphamide Ciclophosphamide [INN] Clafen Claphene Cycloblastin Cyclophosphamid Cyclophosphamide Cyclophosphamide (INN) Cyclophosphamide (TN) Cyclophosphamide (anhydrous form) Cyclophosphamide (anhydrous) Cyclophosphamide Monohydrate Cyclophosphamide Sterile Cyclophosphamide anhydrous Cyclophosphamide, (+-)-Isomer Cyclophosphamides Cyclophosphamidum Cyclophosphamidum [INN-Latin] Cyclophosphan Cyclophosphane Cyclophosphanum Cyclophosphoramide Cyclostin Cyklofosfamid Cyklofosfamid [Czech] Cytophosphan Cytophosphane Cytoxan Cytoxan (TN) Cytoxan Lyoph D,L-Cyclophosphamide D07760 | DB00531 DivK1c_000246 EINECS 200-015-4 EU-0100238 Endoxan Endoxan R Endoxan-Asta Endoxana Endoxanal Endoxane Enduxan Genoxal HMS2090A12 HSDB 3047 Hexadrin IDI1_000246 KBio1_000246 KBio2_001338 KBio2_003906 KBio2_006474 KBio3_001319 KBioGR_000888 KBioSS_001338 LS-1302 LS-99787 Ledoxina Lopac-C-0768 Lopac0_000238 Lyophilized Cytoxan Mitoxan MolPort-001-783-420 N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide NCGC00015209-01 NCGC00015209-03 NCGC00015209-06 NCGC00091741-02 NCGC00091741-03 NCI-C04900 NCI60_002097 NINDS_000246 NSC 26271 NSC-26271 NSC26271 NSC273033 NSC273034 Neosar Occupation, cyclophosphamide exposure Procytox RCRA waste no. U058 Rcra Waste Number U058 Rcra waste number U058 Revimmune S1217_Selleck SK 20501 SPBio_001071 STK177249 STOCK2S-91217 Semdoxan Sendoxan Senduxan Spectrum2_001146 Spectrum3_000370 Spectrum4_000304 Spectrum5_000795 Spectrum_000858 UNII-6UXW23996M WLN: T6MPOTJ BO BN2G2G Zyklophosphamid Zyklophosphamid [German] bis(2-Chloroethyl)phosphami de cyclic propanolamide bis(2-Chloroethyl)phosphamide cyclic propanolamide ester cyclophosphamide |
| | 30 | | Thiotepa | approved | Phase 3, Phase 2, Phase 1 | 226 | 52-24-4 | 5453 | | | 31 | | Cisplatin | approved | Phase 3, Phase 2 | 2770 | 15663-27-1 | 84093, 441203, 2767 | (SP-4-1)-diamminedichloridoplatinum (SP-4-1)-diamminedichloroplatinum (SP-4-2)-diamminedichloridoplatinum (SP-4-2)-diamminedichloroplatinum Abiplatin Biocisplatinum Briplatin CACP CDDP CHEBI:35852 CID441203 CPD0-1392 CPDC CPDD Carboquone Cis Pt II Cis-DDP Cis-Diaminedichloroplatinum Cis-Diamminedichloroplatinum Cismaplat Cisplatine Cisplatino Cisplatinum Cisplatyl Citoplationo DB00515 DDP DDPT Diamminedichloroplatinum | EU-0100918 Lederplatin Neoplatin Peyrone's chloride Peyrone's salt Plastin Platamine Platiblastin Platidiam Platinex Platinol Platinol-AQ Platinoxan Platinum Ammine Chloride Platinum Ammonium Chloride Platinum Diamine Dichloride Randa Trans-DDP Trans-Diaminedichloroplatinum Trans-Diamminedichloroplatinum Trans-Dichlorodiammine Platinum Trans-Platinumdiammine Dichloride cis-DDP cis-Diamminedichloroplatinum cis-Dichlorodiammineplatinum(II) cis-[PtCl2(NH3)2] cis-diamminedichloridoplatinum(II) cis-diamminedichloroplatinum(II) nchembio773-comp1 trans-diamminedichloridoplatinum(II) | |
| | 32 | | Mesna | approved | Phase 3, Phase 2, Phase 1 | 263 | 3375-50-6 | 598 | 2-Mercaptoethane 2-Mercaptoethanesulfonate 2-Mercaptoethanesulfonic acid 2-mercaptoethanesulfonic acid 2-mercaptoethanesulphonic acid 2-mercaptoethylsulfonate 2-sulfanylethylsulfonate | CoM Coenzima M Coenzym M Coenzyme M HS-CoM reduced CoM reduced coenzyme M β-mercaptoethanesulfonic acid | |
| | 33 | | Doxorubicin | approved, investigational | Phase 3, Phase 2 | 1751 | 23214-92-8 | 31703 | (1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside (8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione 111266-55-8 14-Hydroxydaunomycin 14-Hydroxydaunorubicine 14-hydroxydaunomycin 14-hydroxydaunorubicine 23214-92-8 23257-17-2 24385-08-8 25311-50-6 25316-40-9 25316-40-9 (hydrochloride) 29042-30-6 AC1L1M5T AC1Q29OJ ADM ADR Adriablastin Adriacin (hydrochloride salt) Adriamycin Adriamycin PFS Adriamycin PFS (hydrochloride salt) Adriamycin RDF Adriamycin RDF (hydrochloride salt) Adriamycin Semiquinone Adriamycin semiquinone Adriblas tina Adriblastin Adriblastina Adriblastina (TN) Adriblastina (hydrochloride salt) Aerosolized Doxorubicin BPBio1_000502 BRD-K92093830-003-04-3 BSPBio_000456 BSPBio_001031 C01661 C27H29NO11 CCRIS 739 CHEBI:28748 CHEMBL179 CID31703 Caelyx Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74 Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120 D03899 DB00997 DM2 DOX-SL Doxil Doxo Doxorubicin Doxorubicin (USAN/INN) Doxorubicin HCl | Doxorubicin Hydrochloride Doxorubicin [USAN:INN:BAN] Doxorubicin citrate Doxorubicin hydrochloride (hydrochloride salt) Doxorubicin-P4/D10 Doxorubicin-P4/D10 conjugate Doxorubicin-hLL1 Doxorubicin-hLL1 conjugate Doxorubicina Doxorubicina [INN-Spanish] Doxorubicine Doxorubicine [INN-French] Doxorubicinum Doxorubicinum [INN-Latin] EINECS 245-495-6 FI 106 Farmablastina (hydrochloride salt) HMS2089H06 HSDB 3070 Hydroxydaunomycin hydrochlor ide (hydrochloride salt) Hydroxydaunomycin hydrochloride (hydrochloride salt) Hydroxydaunorubicin Hydroxydaunorubicin hydrochloride (hydrochloride salt) JT9100000 LMPK13050001 LS-1029 LS-165655 MLS000759533 Myocet NCI-C01514 NChemBio.2007.10-comp13 NDC 38242-874 NIOSH/JT9100000 NSC 123127 Prestwick0_000438 Prestwick1_000438 Prestwick2_000438 Prestwick3_000438 Probes1_000151 Probes2_000129 RDF Rubex Resmycin Rubex Rubex (hydrochloride salt) SMP1_000106 SPBio_002395 TLC D-99 ThermoDox Triferric doxorubicin UNII-80168379AG adiblastine (hydrochloride salt) adr iablatina (hydrochloride salt) adriablastine (hydrochloride salt) adriablatina (hydrochloride salt) adriblatina (hydrochloride salt) doxorubicin nchembio809-comp5 |
| | 34 | | Topotecan | approved, investigational | Phase 3, Phase 2, Phase 1 | 349 | 119413-54-6, 123948-87-8 | 60700 | (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione 123948-87-8 9-Dimethylaminomethyl-10-hydroxycamptothecin 9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin AC-11592 AC1L1TQZ AC1Q6APZ BSPBio_002348 C11158 C23H23N3O5 CCRIS 8163 CHEBI:107501 CHEBI:46035 CHEMBL84 CID60700 D08618 DB01030 HMS2090B20 HSCI1_000228 Hycamptamine Hycamptin Hycamtamine Hycamtin Hycamtin (TN) LS-127395 | MLS000759456 NCGC00178695-01 NCI60_004771 NCIStruc1_001659 NCIStruc2_001796 NChemBio.2007.10-comp24 NSC609699 SK&F-104864-A SKF 104864 SKF-104864-A SKF-S 104864 SMP2_000312 SMP2_000327 SMR000466344 TOPO TOPOTECAN, HYCAMTIN TPT TTC Topotecan (BAN) Topotecan Hcl Topotecan Hydrochloride Topotecan Lactone Topotecan Monohydrochloride, (S)-Isomer Topotecan [INN:BAN] Topotecan lactone Topotecane Topotecane [INN-French] Topotecanum Topotecanum [INN-Latin] UNII-7M7YKX2N15 topotecan |
| | 35 | | Doxil | Approved June 1999 | Phase 3, Phase 2 | 1751 | | 31703 | | Evacet LipoDox Pegylated Liposomal Doxorubicin Hydrochloride liposomal doxorubicin |
| | 36 | | Immunosuppressive Agents | | Phase 3, Phase 2, Phase 1, Early Phase 1 | 13086 | | | | 37 | | Iodine | | Phase 3, Phase 2, Phase 1 | 570 | 7553-56-2 | 807 | | Iodio Iodum Jod Jood Tincture iodine |
| | 38 | | cadexomer iodine | | Phase 3, Phase 2, Phase 1 | 537 | | | | 39 | | topoisomerase I inhibitors | | Phase 3, Phase 2, Phase 1 | 1370 | | | | 40 | | Antineoplastic Agents, Alkylating | | Phase 3, Phase 2, Phase 1, Early Phase 1 | 4603 | | | | 41 | | Anti-Infective Agents, Local | | Phase 3, Phase 2 | 1880 | | | | 42 | | Antibiotics, Antitubercular | | Phase 3, Phase 2, Phase 1 | 7180 | | | | 43 | | Alkylating Agents | | Phase 3, Phase 2, Phase 1, Early Phase 1 | 4827 | | | | 44 | | Antirheumatic Agents | | Phase 3, Phase 2, Phase 1, Early Phase 1 | 10956 | | | | 45 | | Micronutrients | | Phase 3, Phase 2 | 6001 | | | | 46 | | Trace Elements | | Phase 3, Phase 2 | 6001 | | | | 47 | | Anti-Bacterial Agents | | Phase 3, Phase 2, Phase 1, Early Phase 1 | 11226 | | | | 48 | | Anesthetics | | Phase 3, Phase 2 | 9596 | | | | 49 | | Ranibizumab | approved | Phase 2, Phase 1 | 486 | 347396-82-1 | 459903 | 347396-82-1 D05697 Lucentis Lucentis (TN) | Ranibizumab Ranibizumab (USAN/INN) Ranibizumab (genetical recombination) Ranibizumab (genetical recombination) (JAN) ranibizumab rhuFab V2 |
| | 50 | | Arsenic trioxide | approved, investigational | Phase 2 | 122 | 1327-53-3 | 518740 | 28380-38-3 AC1L24QX AI3-01163 Acide Arsenieux Acide Arsenieux [French] Acide arsenieux [French] Anhydride Arsenieux Anhydride Arsenieux [French] Anhydride arsenieux [French] Arseneous anhydride Arseneous oxide Arseni Trioxydum Arseni trioxydum Arsenic Blanc Arsenic Blanc [French] Arsenic Oxide Arsenic Oxidearsenous Trioxide Arsenic Sesquioxide Arsenic Trioxide [UN1561] [Poison] Arsenic blanc [French] Arsenic oxide Arsenic oxide (As2O3) Arsenic sesquioxide Arsenic trioxide (JP15/USAN) Arsenic trioxide [JAN] Arsenic trioxide [UN1561] [Poison] Arsenic(III) oxide Arsenic(III) trioxide Arsenic, White Arsenicum Album Arsenicum album Arsenigen Saure Arsenigen Saure [German] Arsenigen saure [German] Arsenious Acid Arsenious Acid Anhydride Arsenious Oxide Arsenious Trioxide Arsenious trioxide Arsenite Arsenolite Arsenous Acid | Arsenous Acid Anhydride Arsenous Anhydride Arsenous Oxide Arsenous Oxide Anhydride Arsenous oxide [ISO] Arsenox Arsentrioxide Arsodent C006632 CCRIS 5455 CHEMBL405991 CID14888 Caswell No. 059 Claudelite Claudetite Crude Arsenic D02106 Di-Arsenic Trioxide Diarsenic Trioxide Diarsenic trioxide Diarsonic Trioxide EINECS 215-481-4 EPA Pesticide Chemical Code 007001 HSDB 419 LS-761 MolPort-006-823-587 Oxyde Arsenieux Oxyde Arsenieux [ISO-French] Poison Flour RCRA waste no. P012 Rcra waste number P012 Tetraarsenic hexaoxide Trisenox Trisenox (TN) Trixenox UN 1561 UN1561 UNII-S7V92P67HO White Arsenic White arsenic arsenic trioxide arsenic(3+) naonobin oxygen(2-) |
|
Interventional clinical trials: (show top 50)
(show all 114)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma | Completed | NCT02319486 | Phase 4 | | 2 | Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation | Completed | NCT00336531 | Phase 4 | | 3 | Prospective Study of Profile of Hepatic Osteodystrophy in Patients With Non-Choleastatic Liver Cirrhosis and Impact of Bisphosphonate Supplementation | Completed | NCT02249741 | Phase 4 | | 4 | The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile Dysfunction | Completed | NCT02413099 | Phase 4 | | 5 | Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study | Completed | NCT02204826 | Phase 4 | | 6 | G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor | Not yet recruiting | NCT02933333 | Phase 4 | | 7 | Carboplatin Periocular Injection for Retinoblastoma | Unknown status | NCT02137928 | Phase 3 | | 8 | Does Posterior Reconstruction of the Rhabdosphincter Improve Early Recovery of Continence After Robotic-Assisted Radical Prostatectomy? | Unknown status | NCT01809522 | Phase 3 | | 9 | Systemic Vincristine, Carboplatin, and Etoposide, Subtenon Carboplatin, and Local Ophthalmic Therapy in Treating Children With Intraocular Retinoblastoma | Completed | NCT00072384 | Phase 3 | | 10 | Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma | Completed | NCT00079417 | Phase 3 | | 11 | Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma | Completed | NCT00335738 | Phase 3 | | 12 | Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation | Recruiting | NCT01906814 | Phase 3 | | 13 | Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma | Active, not recruiting | NCT00554788 | Phase 3 | | 14 | Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma | Active, not recruiting | NCT00186888 | Phase 3 | | 15 | Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer | Active, not recruiting | NCT01987596 | Phase 3 | | 16 | Efficacy Study of Lucentis in the Treatment of Retinoblastoma | Unknown status | NCT01899066 | Phase 2 | | 17 | Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma | Unknown status | NCT00179920 | Phase 2 | | 18 | Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia | Unknown status | NCT01761227 | Phase 2 | | 19 | Chemotherapy in Treating Patients With Retinoblastoma | Completed | NCT00002675 | Phase 2 | | 20 | Carboplatin Plus Vincristine in Treating Children With Retinoblastoma | Completed | NCT00002794 | Phase 2 | | 21 | Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma | Completed | NCT00004006 | Phase 2 | | 22 | Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma | Completed | NCT00901238 | Phase 1, Phase 2 | | 23 | Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. | Completed | NCT01291017 | Phase 2 | | 24 | Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma | Completed | NCT00006102 | Phase 2 | | 25 | High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors | Completed | NCT00003173 | Phase 2 | | 26 | Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors | Completed | NCT00024258 | Phase 2 | | 27 | Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors | Completed | NCT00831844 | Phase 2 | | 28 | Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer | Completed | NCT00002515 | Phase 2 | | 29 | An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma. | Completed | NCT00555906 | Phase 2 | | 30 | Intra-arterial Chemotherapy for Children With Retinoblastoma | Recruiting | NCT00906113 | Phase 1, Phase 2 | | 31 | Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma | Recruiting | NCT01783535 | Phase 2 | | 32 | Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009) | Recruiting | NCT02870907 | Phase 2 | | 33 | Conservative Treatments of Retinoblastoma | Recruiting | NCT02866136 | Phase 2 | | 34 | Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer | Recruiting | NCT03130439 | Phase 2 | | 35 | Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy | Recruiting | NCT02334527 | Phase 2 | | 36 | Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression | Recruiting | NCT02555189 | Phase 1, Phase 2 | | 37 | A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | Recruiting | NCT02607124 | Phase 1, Phase 2 | | 38 | Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib | Recruiting | NCT01907607 | Phase 2 | | 39 | PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial | Recruiting | NCT02624973 | Phase 2 | | 40 | Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Cancers | Recruiting | NCT02487095 | Phase 1, Phase 2 | | 41 | Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma | Active, not recruiting | NCT00110110 | Phase 2 | | 42 | A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer | Active, not recruiting | NCT02059213 | Phase 2 | | 43 | A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) | Active, not recruiting | NCT02806648 | Phase 2 | | 44 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | Active, not recruiting | NCT00445965 | Phase 2 | | 45 | Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer | Active, not recruiting | NCT00721409 | Phase 2 | | 46 | A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced B | Active, not recruiting | NCT01684215 | Phase 2 | | 47 | Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma | Not yet recruiting | NCT03024489 | Phase 1, Phase 2 | | 48 | Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala | Terminated | NCT01857752 | Phase 2 | | 49 | Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma | Terminated | NCT01293539 | Phase 2 | | 50 | Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma | Terminated | NCT00432445 | Phase 2 |
Inferred drug relations via UMLS68/NDF-RT46:
|
